Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $100.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price increased by HC Wainwright from $85.00 to $100.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q2 2026 earnings at ($0.97) EPS, Q3 2026 earnings at ($1.26) EPS, FY2026 earnings at ($2.03) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($1.23) EPS, Q3 2027 earnings at ($1.28) EPS, Q4 2027 earnings at ($0.02) EPS and FY2027 earnings at ($3.51) EPS.

A number of other research analysts have also weighed in on ARWR. Morgan Stanley increased their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Bank of America upped their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Royal Bank Of Canada increased their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Chardan Capital raised their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price objective (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $67.05 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The company has a market cap of $9.11 billion, a PE ratio of -838.02 and a beta of 1.21. The company has a 50-day simple moving average of $62.41 and a 200-day simple moving average of $39.95. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76.

Insider Activity

In other news, Director Mauro Ferrari sold 7,530 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $70.00, for a total value of $527,100.00. Following the transaction, the director directly owned 69,053 shares of the company’s stock, valued at $4,833,710. The trade was a 9.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Christopher Richard Anzalone sold 13,187 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total transaction of $871,660.70. Following the sale, the chief executive officer directly owned 3,792,739 shares of the company’s stock, valued at approximately $250,700,047.90. This trade represents a 0.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 510,836 shares of company stock valued at $33,603,060 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 2,923.0% in the fourth quarter. Farther Finance Advisors LLC now owns 11,941 shares of the biotechnology company’s stock worth $793,000 after acquiring an additional 11,546 shares in the last quarter. Financial Enhancement Group LLC purchased a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $373,000. State of Alaska Department of Revenue increased its holdings in Arrowhead Pharmaceuticals by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 70,399 shares of the biotechnology company’s stock valued at $4,673,000 after purchasing an additional 831 shares in the last quarter. Choreo LLC purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $450,000. Finally, Ritholtz Wealth Management acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $262,000. 62.61% of the stock is owned by institutional investors and hedge funds.

More Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near‑term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re‑rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower‑than‑average volume — likely profit‑taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.